Abstract: Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system.

Abstract: Disclosed is the a method of effecting skin hydration and enhancing skin barrier function, said method comprising the step of bringing into contact a pentapeptide conjugate of oleanolic acid with skin cells so that the effect of increased cellular communication at the molecular level to bring about gene and protein expression in the cells of the skin that enable hydration and skin barrier functions are realized.

Abstract: The present invention provides a method of using (E)-1-(3?, 4?-dimethoxyphenyl) butadiene to induce anti-tumorigenic effects in pancreatic carcinoma, ovarian carcinoma, prostate carcinoma, colon carcinoma, lung carcinoma, lymphoblastoma, melanoma and colorectal carcinoma. The invention also provides a method of using (E)-1-(3?, 4?-dimethoxyphenyl) butadiene to prevent cancer metastasis.

Abstract: The present invention provides a method of using (E)-1-(3?, 4?-dimethoxyphenyl) butadiene to induce anti-tumorigenic effects in pancreatic carcinoma, ovarian carcinoma and prostate carcinoma. The invention also provides a method of using (E)-1-(3?, 4?-dimethoxyphenyl) butadiene to prevent cancer metastasis.

Abstract: Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.

Abstract: Disclosed herein is (i) a method related to the growth promotional activity of plant based fibres on Bacillus coagulans MTCC 5856; (ii) the combination of plant based fibres and Bacillus coagulans MTCC 5856 to inhibit Gram Negative pathogenic bacteria; and (iii) the production of short chain fatty acids (SCFA) by Bacillus coagulans MTCC 5856 using plant based fibres.

Abstract: The present invention discloses the potential of Calebin A in attenuating high fat diet (HFD) induced hepatic steatosis in mammals.

Abstract: The present invention disclosed herein describes (i) the growth promotional activity of natural plant based fibres on Bacillus coagulans MTCC 5856; (ii) the combination of natural plant based fibres and Bacillus coagulans MTCC 5856 to inhibit Gram Negative pathogenic bacteria and (iii) the production of short chain fatty acids (SCFA) by Bacillus coagulans MTCC 5856 using plant based natural fibres.

Abstract: The antimicrobial effect of extracellular metabolite composition from Bacillus coagulans MTCC 5856 and composition comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis is described.

Abstract: The antimicrobial effect of extracellular metabolite composition from Bacillus coagulans MTCC 5856 is described.

Abstract: Process of inhibiting microbial biofilm formation using extracellular metabolite composition from Bacillus coagulans MTCC 5856 and composition comprising from about 61% w/w of thymol, about 38% w/w of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis is described.

Abstract: Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.

Abstract: Method of extracting a partially purified extracellular metabolite composition from Bacillus coagulans MTCC 5856 and its antimicrobial effects thereof are described.

Abstract: The present invention discloses a process for the therapeutic management of diarrhea predominant irritable bowel syndrome in humans comprising the oral administration of Bacillus coagulans SBC37-01, MTCC 5856 (containing not less than 2 billion spores) along with standard treatment of care in a specific manner.

Abstract: The present invention discloses selenium peptide based synergistic compositions for the protection (morphology and viable numbers) of dermal papilla cells. The synergistic compositions disclosed in the present invention comprise (a) 1-O-galloyl-?-D-glucose (?-glucogallin) or 1-O-galloyl-?-D-glucose (?-glucogallin) and gallates (b) concentrate of liquid endosperm of Cocos nucifera and (c) selenopeptides.

Abstract: The invention discloses high yielding synthetic process for 3?-hydroxy pterostilbene.

Abstract: Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of Cyperus rotundus.

Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).

Abstract: A novel, bioavailable and safe stilbenoid 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#1 with an unexpected enhanced ability to prevent the accumulation of lipids accompanying the terminal differentiation of adipocytes, thereby inhibiting adipogenesis, and nutraceutical and cosmeceutical compositions comprising 3,5-dimethoxy-3,4?-dihydroxystilbene useful for anti-obesity and anti-cellulite therapy, are disclosed. Further the enhanced SIRT-1 activation ability of 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#1 and 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II are disclosed. The enhancement of SIRT-1 polypeptide activity of the said compounds is unexpectedly much higher than resveratrol or its natural analog pterostilbene. Sirtuin modulating compositions comprising an orally bioavailable SIRT-1 enhancing compounds (i) 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I and (ii) 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II are also disclosed.

Abstract: Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy-3,4?-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3?,5?, 6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed.